UBS Maintains Buy on Denali Therapeutics, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Esther Rajavelu maintains a Buy rating on Denali Therapeutics (NASDAQ:DNLI) but lowers the price target from $70 to $32.
April 09, 2024 | 4:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS maintains a Buy rating on Denali Therapeutics but significantly reduces the price target from $70 to $32.
The reduction in price target by more than half could indicate concerns about Denali Therapeutics' future prospects or valuation, potentially leading to short-term negative sentiment among investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100